Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention  by Mangiacapra, Fabio et al.
P
A
P
C
F
L
A
R
O
b
i
B
r
M
d
t
c
p
R
s
0
p
m
m
C
i
p
F
F
O
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 3 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 1 2 . 0 1 2oint-of-Care Assessment of Platelet Reactivity
fter Clopidogrel to Predict Myonecrosis in
atients Undergoing Percutaneous
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bjectives We sought to evaluate the inﬂuence of platelet reactivity after clopidogrel, as assessed
y the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-
ntermediate risk patients undergoing percutaneous coronary intervention (PCI).
ackground Inadequate platelet inhibition at the time of PCI is associated with a higher risk of
ecurrent ischemic events.
ethods A total of 250 consecutive biomarker-negative patients treated with clopidogrel and un-
ergoing elective PCI were enrolled. Cardiac biomarkers (creatine kinase-myocardial band and
roponin I) were measured before and 8 and 24 h after intervention. Platelet reactivity after
lopidogrel was assessed immediately before PCI by the VerifyNow P2Y12 point-of-care assay. High
latelet reactivity (HPR) after clopidogrel was deﬁned as a platelet reaction unit value 240.
esults Patients with HPR (31% of the overall population) showed more frequent myonecrosis, with
tatistical signiﬁcance with regard to creatine kinase-myocardial band elevation (35% vs. 20%; p 
.011), and by trend with regard to troponin-I elevation (47% vs. 35%; p  0.059). Incidence of
eriprocedural myocardial infarction was higher in patients with HPR, both by creatine kinase-
yocardial band (13% vs. 4%; p  0.011) and troponin-I deﬁnition (32% vs. 19%; p  0.019). By
ultivariable analysis, HPR was an independent predictor of periprocedural myocardial infarction.
onclusions Easily assessed by a point-of-care assay, HPR after clopidogrel is a frequent ﬁnding and
s associated with increased risk of myonecrosis in low-to-intermediate risk patients undergoing
lanned PCI. (J Am Coll Cardiol Intv 2010;3:318–23) © 2010 by the American College of Cardiology
oundation
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319latelet inhibition in patients undergoing percutaneous
oronary intervention (PCI) is of paramount importance to
educe the risk of recurrent ischemic events (1,2). Dual
ntiplatelet therapy with aspirin and clopidogrel is the
trategy most commonly applied (3), although a large
nterindividual variability in clopidogrel response (4) may
esult in an inadequate platelet inhibition at the time of PCI
5–7). The latter has been advocated to partly explain
ost-procedural myonecrosis, although recent studies
6,8–10) have yielded conflicting results, probably due to
eterogeneous methods and definitions employed. Yet, even
mall post-procedural elevations of cardiac markers have
een associated with an increased risk of long-term major
ardiac adverse events, including death (11–15).
The aim of the present study was to evaluate the influence
f platelet reactivity after clopidogrel, as assessed by the
erifyNow point-of-care assay (Accumetrics, San Diego,
alifornia), on myonecrosis in low-to-intermediate risk
atients undergoing PCI.
ethods
atient population. Consecutive patients with negative myocar-
ial biomarkers undergoing elective PCI were recruited. Exclusion
riteria were: acute coronary syndrome, administration of glyco-
rotein IIb/IIIa inhibitors, chronic total occlusion, lesions with
xtensive calcifications requiring rotational atherectomy, plate-
et count 70  109/l, high bleeding risk, coronary bypass
urgery in the previous 3 months, severe chronic renal failure
serum creatinine 2 mg/dl). All patients were on chronic
spirin treatment. They received either 600-mg clopidogrel
oading dose (at least 6 h before intervention) or were on
herapy with clopidogrel 75 mg/day for at least 5 days.
rocedural anticoagulation was performed by administration of
nfractionated heparin (100 U/kg) in all patients. A local
thical committee approved the study and all patients signed
ritten informed consent.
ssessment of biomarkers and platelet reactivity. Blood
amples were drawn in all patients before and 8 and 24 h
fter intervention for cardiac biomarkers assessment (creat-
ne kinase-myocardial band [CK-MB], troponin I [Tn-I]),
sing the Access 2 immunochemiluminometric assay (Beck-
an Coulter, Fullerton, California).
Platelet reactivity after clopidogrel was assessed immedi-
tely before PCI by the VerifyNow P2Y12 point-of-care
ssay. Blood was collected from the femoral artery imme-
iately after sheath placement. Blood samples were collected
n 2-ml tubes containing 3.2% sodium citrate. VerifyNow
2Y12 (Accumetrics) specifically evaluates clopidogrel effect
n P2Y12 receptor by optical turbidimetry. Whole blood is
hallenged in dedicated cartridges with 20 mol adenosine
iphosphate, which activates platelets by binding P2Y1 and
2Y12 receptors, and 22 nmol prostaglandin E1, whichncreases assay specificity by suppressing adenosine diphos- rhate–induced P2Y1-related intraplatelet signaling. Acti-
ated platelets agglutinate around fibrinogen-coated poly-
tyrene beads, therefore increasing light transmittance
hrough the sample. Results are reported as P2Y12 reaction
nits (PRU); the lower the PRU value, the higher the
latelet aggregation inhibition by clopidogrel. High platelet
eactivity (HPR) after clopidogrel was defined as a PRU
alue 240 (6).
nd points. Primary end point of the study was the corre-
ation between occurrence of myonecrosis in patients un-
ergoing elective PCI and presence of HPR. Myonecrosis
as defined as any increase of cardiac biomarkers above the
9th percentile upper limit of normal (ULN). In addition,
orrelation between HPR and increases of biomarkers3
LN and 5 ULN were also evaluated.
Secondary end points were: incidence of HPR in patients
ith and without periprocedural myocardial infarction
PMI), according to the universal definition (16); peak
alues of cardiac biomarkers according to the presence of
PR. In-hospital major adverse
ardiac events (death, myocar-
ial infarction, urgent target ves-
el revascularization) and bleed-
ngs were monitored.
tatistics. In the ARMYDA-
RO (Antiplatelet Therapy for
eduction of Myocardial Dam-
ge During Angioplasty-Platelet
eactivity Predicts Outcome)
tudy (6), mean PRU values
ere 219  69 in patients with
ormal post-PCI CK-MB, and
44  58 in those with post-
rocedural increase of CK-MB.
hus, assuming a CK-MB in-
rease in 30% of patients and expecting in these a mean
RU value 12% higher than in those without myonecrosis,
total of 246 patients were needed to detect the expected
ifference between the 2 groups with an estimated power of
0% at a 2-sided alpha of 0.05.
Continuous variables are expressed as mean SD, unless
therwise specified. Categorical variables are reported as
requencies and percentages. Comparisons between contin-
ous variables were performed by Student t test, or Mann-
hitney U test if not normally distributed. Comparisons
etween categorical variables were evaluated using 2-tailed
isher exact test or Pearson chi-square test, as appropriate.
ormal distribution of PRU levels in the study population
as confirmed by Kolmogorov-Smirnov test. All clinical
nd procedural features and presence of HPR were evalu-
ted in a univariate analysis for the association with PMI
sing logistic regression. Only variables showing a p value
0.15 were then entered into a multivariable logistic
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
HPR  high platelet
reactivity
PCI  percutaneous
coronary intervention
PMI  periprocedural
myocardial infarction
PRU  P2Y12 reaction units
Tn-I  troponin I
ULN  upper limit of normalegression model. Statistical analysis was performed using
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320PSS version 15.0 software (SPSS Inc., Chicago, Illinois)
nd p values 0.05 were considered significant.
esults
tudy population. A total of 250 patients were recruited in
he study. Mean PRU value in the general population was
07 65; 78 patients (31%) showed a PRU240 and were
ssigned to the HPR group (Fig. 1). Clinical and procedural
eatures are listed in Tables 1 and 2, respectively. Diabetes
ellitus was more frequent among patients with HPR (42%
s. 29% in patients with normal platelet reactivity; p 
.039), who also tended to have higher body mass index
nd, more commonly, a multivessel disease. Procedural
uccess was achieved in all patients and no bailout use of
lycoprotein IIb/IIIa inhibitors was required.
rimary end point. Myonecrosis was significantly more fre-
uent in the HPR group (Fig. 2). CK-MB increase was
ore frequent in patients with HPR with respect to any
levation (35% vs. 20%; odds ratio [OR]: 2.15; 95% confi-
ence interval [CI]: 1.18 to 3.91; p 0.011), more than 3
LN (13% vs. 4%; OR: 3.47; 95% CI: 1.27 to 9.48; p 
.011), and more than 5 ULN (6% vs. 1%; OR: 5.82; 95%
I: 1.10 to 30.70; p  0.020). Whereas there was no
ignificant difference between the 2 groups with respect to
ny elevation of Tn-I (47% vs. 35%; OR: 1.69; 95% CI: 0.98
o 2.90; p 0.059), patients with HPR showed significantly
ore frequent increases in Tn-I when the value was more
han 3 ULN (32% vs. 19%; OR: 2.06; 95% CI: 1.12 to
.80; p 0.019) and also when the value was more than 5
LN (21% vs. 6%; OR: 4.18; 95% CI: 1.80 to 9.71; p 
.001). Mean PRU value was significantly higher in patients
ith CK-MB increase, as compared with patients without
227  71 vs. 200  62; p  0.006).
econdary end points. A total of 57 (23%) patients met the
riteria for PMI (16). We found HPR was more frequent in
Figure 1. Platelet Reactivity
Distribution of platelet reactivity assessed by VerifyNow P2Y12 assay. PRU  Patients with PMI (44% vs. 28% of patients without PMI;R: 2.06; 95% CI: 1.12 to 3.80, p  0.019) (Fig. 3). The
edian peak value of Tn-I was significantly higher in the
PR group (0.07, interquartile range [IQR]: 0.03 to 0.30
s. 0.04, IQR: 0.01 to 0.16; p 0.002), whereas the median
eak value of CK-MB was not significantly different be-
ween the 2 groups (2.4, IQR: 1.1 to 5.0 vs. 1.9, IQR: 1.1
o 3.4; p  0.098). No significant correlation was found
etween PRU values and peak levels CK-MB or Tn-I. No
ajor adverse cardiac events, other than PMI, or major
eaction unit.
Table 1. Clinical Characteristics
HPR
(n  78)
No HPR
(n  172) p Value
Age, yrs 66.5 9.6 65.4 9.8 0.405
Male 66 (85) 134 (78) 0.219
Body mass index, kg/m2 26.6 3.1 25.9 3.2 0.103
Diabetes mellitus 33 (42) 50 (29) 0.039
Hypertension 60 (77) 128 (74) 0.671
Hyperlipidemia 60 (77) 124 (72) 0.422
Current smoker 13 (17) 40 (23) 0.238
Previous myocardial infarction 24 (31) 44 (26) 0.393
Previous coronary intervention 28 (36) 73 (42) 0.329
Previous bypass surgery 4 (5) 9 (5) 0.972
Left ventricle ejection fraction, % 56 7 56 8 0.842
Creatinine, mg/dl 1.10 0.31 1.11 0.29 0.810
Baseline medications
Aspirin 78 (100) 172 (100) 1.000
Clopidogrel 9 (12) 19 (11) 0.909
Statin 69 (88) 146 (85) 0.450
Calcium channel blocker 20 (26) 40 (23) 0.207
Proton pump inhibitor 22 (28) 48 (28) 0.961
Clinical presentation 0.571
Stable angina 14 (18) 26 (15)
Unstable angina 64 (82) 146 (85)
PRU 281 34 173 44 0.001
Values are mean SD or n (%).HPR high platelet reactivity; PRU P2Y12 reaction unit.
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321leeding occurred during hospitalization. Nine minor
leedings were recorded, irrespective of HPR.
ultivariable analysis. At univariate analysis, multivessel
ntervention, lesion type B2/C, multivessel disease, diabetes,
nd HPR were significantly associated with PMI by
K-MB definition, whereas total stent length, left ventricle
jection fraction 40%, multivessel disease, and HPR were
ignificantly associated with PMI by Tn-I definition. Mul-
ivariable analysis (Fig. 4) showed that HPR was an inde-
endent predictor of increased risk of PMI either by
Table 2. Procedural Characteristics
HPR
(n  78)
No HPR
(n  172) p Value
Treated vessel 0.748
Left anterior descending 46 (50) 103 (48)
Left circumﬂex 20 (22) 51 (24)
Right coronary artery 26 (28) 56 (26)
Saphenous vein graft — 4 (2)
Restenotic lesion 9 (11) 22 (13) 0.781
Lesion type B2/C 62 (67) 132 (62) 0.342
Bifurcation lesions 46 (27) 25 (32) 0.389
Multivessel intervention 14 (18) 38 (22) 0.454
Use of stent 77 (99) 169 (98) 0.787
Use of drug-eluting stent 20 (26) 41 (24) 0.758
Direct stenting, % 38 (49) 89 (52) 0.657
Stents implanted 1.4 0.6 1.5 0.7 0.249
Total stent length, mm 28 17 29 16 0.662
Post-dilation, % 29 (37) 67 (39) 0.789
Maximal inﬂation pressure, atm 15.0 3.8 15.1 4 0.850
Side branch occlusion 2 (3) 3 (2) 0.668
Values are n (%) or mean SD.
Abbreviations as in Table 1.
Figure 2. Platelet Reactivity and Myonecrosis
Incidence of myonecrosis in patients with (green bars) and without (orange b
ponin I; ULN  upper limit of normal.K-MB definition (OR: 3.21; 95% CI: 1.11 to 9.32; p 
.032) (Fig. 4A) or Tn-I definition (OR: 2.25; 95% CI:
.24 to 4.13; p  0.019) (Fig. 4B).
iscussion
n the present study, high residual platelet reactivity after
lopidogrel was detected in almost one-third of the patients
nd appeared to be an independent predictor of PMI. Our
esults confirm the predictive role of post-clopidogrel plate-
et reactivity on myocardial injury during coronary interven-
ion, as previously shown (6,10). Yet, Lev et al. (8) found
nly a trend toward increased myonecrosis in clopidogrel-
esistant patients and Buch et al. (9) did not observe any
igh platelet reactivity. CK-MB  creatine kinase-myocardial band; Tn-I  tro-
Figure 3. Platelet Reactivity and PMI
Incidence of high platelet reactivity (HPR) according to the presence of
periprocedural myocardial infarction (PMI).ars) h
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322ignificant correlation between PRU values and cardiac
iomarkers levels. Lack of cutoff values for impaired re-
ponse to clopidogrel in these studies might have accounted
or discrepancies. Conversely, we divided the study popula-
ion based on the presence of HPR after clopidogrel,
efined as a PRU value 240 by VerifyNow assay. In the
RMYDA-PRO study (6), a PRU value 240 was found
o be an optimal cutoff to discriminate patients at higher risk
f 30-day major adverse cardiovascular events. More re-
ently, Marcucci et al. (7) showed the same PRU threshold
alue to predict higher risk of 12-month cardiovascular
eath and non-fatal myocardial infarction in 683 patients
ndergoing PCI for acute coronary syndrome. Furthermore,
similar cutoff value (PRU 235) was able to significantly
redict stent thrombosis after drug-eluting stent implanta-
ion (5). Beyond clinical significance, our definition of HPR
s also supported by previous evidence that a PRU value
239 was the optimal cutoff for predicting high post-
reatment platelet reactivity, defined as a 5-mol/l adeno-
ine diphosphate–induced platelet aggregation 50% by
ight transmittance aggregometry in 300 PCI patients (17).
In our study, HPR was significantly associated with
eriprocedural myonecrosis, consistently over different de-
rees of post-procedural cardiac biomarkers elevations. Al-
hough the prognostic value of procedure-related myone-
rosis is still under debate (18,19), growing evidence
upports that even small increases of CK-MB (11–13)
Figure 4. Multivariable Analysis
Odds ratios (presented on log axis) for periprocedural myocardial infarction
by creatine kinase-myocardial band (A) and troponin (B) deﬁnition. LVEF 
left ventricular ejection fraction; other abbreviations as in Figure 3.nd troponin (14,15) are significantly associated with long- oerm clinical events, including mortality. Selvanayagam et
l. (20) provided important insights on the mechanism
inking periprocedural myonecrosis and long-term-
utcome. An irreversible myocardial injury detected by
elayed-enhancement magnetic resonance imaging was ob-
erved in patients with post-procedural troponin elevation.
n addition, the risk of adverse events increases proportion-
lly with cardiac markers elevation (11,21), translating into
n even higher risk for patients with PMI (16).
linical implications. Assessment of platelet reactivity by a
apid and user-friendly point-of care assay, in combination
ith the use of a validated threshold value, can be a useful
ool for discriminating patients with HPR despite clopi-
ogrel therapy, who are therefore at increased risk of
yonecrosis. In such patients, a more aggressive antiplatelet
reatment may be indicated to prevent further ischemic
vents. Recent reports have shown, in fact, a particularly
eneficial effect of glycoprotein IIb/IIIa inhibitors in pa-
ients with impaired response to clopidogrel (22–24). A
ubstudy of the BRIEF-PCI (Brief Infusion of Intravenous
ptifibatide Following Successful-Percutaneous Coronary
ntervention) trial (22), demonstrated that incidence of
ost-procedural myonecrosis was not affected by response to
lopidogrel in patients receiving eptifibatide. Furthermore,
n a relatively small study on 149 clopidogrel nonresponders
ndergoing PCI, administration of abciximab significantly
educed rates of 30-day cardiovascular events, which were
ainly driven by periprocedural myonecrosis (23). Similarly,
algimigli et al. (24) have recently shown that in patients
ith poor responsiveness to clopidogrel, tirofiban adminis-
ration can significantly decrease incidence of PMI, both by
K-MB and troponin definition.
Novel thienopyridines represent another therapeutic op-
ion in patients with impaired response to clopidogrel in
rder to prevent myonecrosis. In a subanalysis of the
RITON–TIMI 38 (Trial to Assess Improvement in Ther-
peutic Outcomes by Optimizing Platelet Inhibition with
rasugrel–Thrombolysis In Myocardial Infarction 38) study
25), treatment with prasugrel was superior to clopidogrel in
educing the risk of recurrent myocardial infarction, includ-
ng those related to the procedure, in patients with acute
oronary syndrome undergoing PCI.
tudy limitations. By study protocol, only patients with
ow-to-intermediate risk PCI and baseline negative cardiac
iomarkers were enrolled, therefore we cannot extend our
esults to more complex patients or acute coronary syn-
rome. However, low-to-intermediate risk patients are
recisely those patients highly exposed to myonecrosis
hould platelet inhibition play a critical role, whereas coro-
ary manipulation and side branch occlusion might indeed
e more important determinants in more complex cases. We
nly monitored patients during in-hospital period, thus no
ata about the influence of platelet reactivity on long-term
utcome are available.
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323onclusions
asily assessed by a point-of-care assay, HPR after clopi-
ogrel is a frequent finding and is associated with increased
isk of myonecrosis in low-to-intermediate risk patients
ndergoing PCI. In patients with HPR, tailored antiplatelet
herapy may be required to reduce procedural complications.
eprint requests and correspondence: Prof. Germano Di
ciascio, Department of Cardiovascular Sciences, Campus Bio-
edico University, Via Álvaro del Portillo, 200, Rome 00128,
taly. E-mail: g.disciascio@unicampus.it.
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